Kinase genotype analysis of gastric gastrointestinal stromal tumor cytology samples using targeted next-generation sequencing

Clinical Gastroenterology and Hepatology

Volumn 13, Issue 1, 2015, Pages 202-206

  Gleeson, Ferga C ^a   Kipp, Benjamin R ^a   Kerr, Sarah E ^a   Voss, Jesse S ^a   Graham, Rondell P ^a   Campion, Michael B ^a   Minot, Douglas M ^a   Tu, Zheng J ^a   Klee, Eric W ^a   Lazaridis, Konstantinos N ^a   Henry, Michael R ^a   Levy, Michael J ^a  

^a MAYO CLINIC   (United States)

Author keywords

EUS FNA; Molecular genetics; Personalized medicine; Targeted therapy; Tyrosine kinase inhibitor

Indexed keywords

IMATINIB; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PROTEIN TYROSINE KINASE; STEM CELL FACTOR RECEPTOR;

AGED; ARTICLE; BRAF GENE; CANCER RESISTANCE; CANCER THERAPY; CLINICAL ARTICLE; CYTOLOGY; DNA SEQUENCE; ENDOSCOPIC ULTRASOUND GUIDED FINE NEEDLE BIOPSY; FEMALE; FGFR3 GENE; GASTROINTESTINAL STROMAL TUMOR; GENE; GENE MUTATION; GENOTYPE; HUMAN; KIT GENE; KRAS GENE; MALE; MICROARRAY KIT; MOLECULAR GENETICS; NEXT GENERATION SEQUENCING; PDGFRA GENE; PIK3CA GENE; TREATMENT RESPONSE; ADULT; FINE NEEDLE ASPIRATION BIOPSY; GASTROINTESTINAL STROMAL TUMORS; GENETICS; GENOTYPING TECHNIQUE; HIGH THROUGHPUT SEQUENCING; MIDDLE AGED; PATHOLOGY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BIOPSY, FINE-NEEDLE; FEMALE; GASTROINTESTINAL STROMAL TUMORS; GENOTYPE; GENOTYPING TECHNIQUES; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MALE; MIDDLE AGED; PROTO-ONCOGENE PROTEINS C-KIT; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA;

EID: 84916898189     PISSN: 15423565     EISSN: 15427714     Source Type: Journal    
DOI: 10.1016/j.cgh.2014.06.024     Document Type: Article

References (22)

1. Corless C.L., Schroeder A., Griffith D., et al. PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and invitro sensitivity to imatinib. JClin Oncol 2005, 23:5357-5364.
2. Campanella N.C., de Oliveira A.T., Scapulatempo-Neto C., et al. Biomarkers and novel therapeutic targets in gastrointestinal stromal tumors (GISTs). Recent Pat Anticancer Drug Discov 2013, 8:288-297.
3. Cassier P.A., Fumagalli E., Rutkowski P., et al. European Organisation for Research and Treatment of Cancer. Outcome of patients with platelet-derived growth factor receptor alpha-mutated gastrointestinal stromal tumors in the tyrosine kinase inhibitor era. Clin Cancer Res 2012, 18:4458-4464.
4. Künstlinger H., Huss S., Merkelbach-Bruse S., et al. Gastrointestinal stromal tumors with KIT exon 9 mutations: update on genotype-phenotype correlation and validation of a high-resolution melting assay for mutational testing. Am J Surg Pathol 2013, 37:1648-1659.
5. Heinrich M.C., Corless C.L., Demetri G.D., et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. JClin Oncol 2003, 21:4342-4349.
6. Bednarski B.K., Araujo D.M., Yi M., et al. Analysis of prognostic factors impacting oncologic outcomes after neoadjuvant tyrosine kinase inhibitor therapy for gastrointestinal stromal tumors. Ann Surg Oncol 2014, 21:2499-2505.
7. Joensuu H., Hohenberger P., Corless C.L. Gastrointestinal stromal tumour. Lancet 2013, 382:973-983.
8. Gleeson F.C., Kipp B.R., Campion M.B., et al. Oncogene mutation analysis of archived lymph node endoscopic ultrasound fine needle aspirates (EUS FNA) from locally advanced sporadic rectal cancer using next generation sequencing (NGS) technology. Gastrointest Endosc 2013, 77(Suppl):AB366.
9. Cock P.J., Fields C.J., Goto N., et al. The Sanger FASTQ file format for sequences with quality scores, and the Solexa/Illumina FASTQ variants. Nucleic Acids Res 2010, 38:1767-1771.
10. Li H., Handsaker B., Wysoker A., et al. The sequence alignment/map format and SAMtools. Bioinformatics 2009, 25:2078-2079. 1000 Genome Project Data Processing Subgroup.
11. Gomes A.L., Bardales R.H., Milanezi F., et al. Molecular analysis of c-Kit and PDGFRA in GISTs diagnosed by EUS. Am J Clin Pathol 2007, 127:89-96.
12. Nodit L., McGrath K.M., Zahid M., et al. Endoscopic ultrasound-guided fine needle aspirate microsatellite loss analysis and pancreatic endocrine tumor outcome. Clin Gastroenterol Hepatol 2006, 4:1474-1478.
13. Levy M.J., Oberg T.N., Campion M.B., et al. Comparison of methods to detect neoplasia in patients undergoing endoscopic ultrasound-guided fine-needle aspiration. Gastroenterology 2012, 142:1112-1121.
14. Bournet B., Pointreau A., Souque A., et al. Gene expression signature of advanced pancreatic ductal adenocarcinoma using low density array on endoscopic ultrasound-guided fine needle aspiration samples. Pancreatology 2012, 12:27-34.
15. Ulivi P., Romagnoli M., Chiadini E., et al. Assessment of EGFR and K-ras mutations in fixed and fresh specimens from transesophageal ultrasound-guided fine needle aspiration in non-small cell lung cancer patients. Int J Oncol 2012, 41:147-152.
16. van Eijk R., Licht J., Schrumpf M., et al. Rapid KRAS, EGFR, BRAF and PIK3CA mutation analysis of fine needle aspirates from non-small-cell lung cancer using allele-specific qPCR. PLoS One 2011, 6:e17791.
17. Kelley R.K., Venook A.P. Nonadherence to imatinib during an economic downturn. NEngl J Med 2010, 363:596-598.
18. Sanon M., Taylor D.C., Parthan A., et al. Cost-effectiveness of 3-years of adjuvant imatinib in gastrointestinal stromal tumors (GIST) in the United States. JMed Econ 2013, 16:150-159.
19. Heinrich M.C., Owzar K., Corless C.L., et al. Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group. JClin Oncol 2008, 26:5360-5367.
20. Debiec-Rychter M., Sciot R., Le Cesne A., et al. EORTC Soft Tissue and Bone Sarcoma Group; Italian Sarcoma Group; Australasian GastroIntestinal Trials Group. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur J Cancer 2006, 42:1093-1103.
21. Sendur M.A., Ozdemir N.Y., Akinci M.B., et al. Is exon mutation analysis needed for adjuvant treatment of gastrointestinal stromal tumor?. World J Gastroenterol 2013, 19:144-146.
22. Miranda C., Nucifora M., Molinari F., et al. KRAS and BRAF mutations predict primary resistance to imatinib in gastrointestinal stromal tumors. Clin Cancer Res 2012, 18:1769-1776.